{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:17:07Z","timestamp":1794323827212,"version":"4.9.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA142543"],"award-info":[{"award-number":["P30CA142543"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.urolonc.2025.01.015","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T17:25:22Z","timestamp":1739640322000},"page":"391.e1-391.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8877-6799","authenticated-orcid":false,"given":"Thomas","family":"Gerald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon L.","family":"Woldu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Halstuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaara","family":"Ber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lifshitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grayden","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franto","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Margel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2025.01.015_bib0001","first-page":"17","article-title":"Cancer statistics","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2025.01.015_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1170124","article-title":"Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs","volume":"13","author":"Grabe-Heyne","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.015_bib0003","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0022-5347(17)55282-9","article-title":"Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer","volume":"124","author":"Lamm","year":"1980","journal-title":"J Urol"},{"issue":"359","key":"10.1016\/j.urolonc.2025.01.015_bib0004","article-title":"Treatment of superficial bladder cancer with intravesical BCG (abstract C-160)","volume":"21","author":"Camacho","year":"1980","journal-title":"Proc Am Assoc Cancer Res Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.015_bib0005","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.juro.2016.02.3005","article-title":"Immunotherapy for the treatment of urothelial carcinoma","volume":"197","author":"Donin","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.01.015_bib0006","unstructured":"EAU Guidelines. Edn. Presented at the EAU Annual Congress Milan 2023. https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladder-cancer. Accessed June 22, 2023."},{"issue":"5","key":"10.1016\/j.urolonc.2025.01.015_bib0007","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.015_bib0008","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.urolonc.2025.01.015_bib0009","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.urolonc.2025.01.015_bib0010","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","article-title":"Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers","volume":"56","author":"Nakanishi","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1016\/j.urolonc.2025.01.015_bib0011","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.015_bib0012","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.annonc.2022.11.012","article-title":"Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up","volume":"34","author":"Balar","year":"2023","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.urolonc.2025.01.015_bib0013","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2025.01.015_bib0014","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.015_bib0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urolonc.2022.12.008","article-title":"Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients","volume":"41","author":"Gerald","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.01.015_bib0016","unstructured":"Administration USDoHaHSFaD. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. https:\/\/www.fda.gov\/media\/101468\/download. Published 2018. Accessed June 20, 2023."},{"key":"10.1016\/j.urolonc.2025.01.015_bib0017","unstructured":"Agilent Technologies I. PD-L1 IHC 22C3 pharmDx interpretation manual - urothelial carcinoma.https:\/\/www.agilent.com\/cs\/library\/usermanuals\/public\/29276_22C3_pharmdx_uc_interpretation_manual_us.pdf. Published 2021. Accessed December 16, 2022."},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.015_bib0018","first-page":"48","article-title":"Evidence base medicine; part 4: pre and post test probabilities and Fagan's nomogram","volume":"4","author":"Safari","year":"2016","journal-title":"Emergency"},{"issue":"3","key":"10.1016\/j.urolonc.2025.01.015_bib0019","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4103\/0301-4738.49397","article-title":"Likelihood ratios: clinical application in day-to-day practice","volume":"57","author":"Parikh","year":"2009","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.urolonc.2025.01.015_bib0020","unstructured":"Prinzi A. Why pretest and posttest probability matter in the time of COVID-19. American Society for Microbiology.https:\/\/asm.org\/articles\/2020\/june\/why-pretest-and-posttest-probability-matter-in-the. Published 2020. Accessed November 10, 2024, 2024."},{"issue":"2","key":"10.1016\/j.urolonc.2025.01.015_bib0021","first-page":"161","article-title":"B7-H3 and PD-L1 expression are prognostic biomarkers in a multi-racial cohort of patients with colorectal cancer","volume":"20","author":"Zhang","year":"2021","journal-title":"Clin Colorectal Cancer"},{"issue":"17","key":"10.1016\/j.urolonc.2025.01.015_bib0022","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1158\/1078-0432.CCR-22-0862","article-title":"Clinical outcomes and immune markers by race in a phase I\/II Clinical trial of Durvalumab concomitant with neoadjuvant chemotherapy in early-stage TNBC","volume":"28","author":"Foldi","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2025.01.015_bib0023","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.juro.2017.04.102","article-title":"Differential expression of PD-L1 in high grade T1 vs muscle invasive bladder carcinoma and its prognostic implications","volume":"198","author":"Wankowicz","year":"2017","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.01.015_bib0024","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1007\/s00345-020-03329-2","article-title":"PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment","volume":"39","author":"Roumiguie","year":"2021","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2025.01.015_bib0025","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1007\/s00345-019-02896-3","article-title":"Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC)","volume":"38","author":"Delcourt","year":"2020","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.01.015_bib0026","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/s41598-019-40145-0","article-title":"Bacillus Calmette-guerin induces PD-L1 expression on antigen-presenting cells via autocrine and paracrine interleukin-STAT3 circuits","volume":"9","author":"Copland","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2025.01.015_bib0027","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/OTT.S165840","article-title":"Bacillus Calmette-Guerin and anti-PD-L1 combination therapy boosts immune response against bladder cancer","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"10","key":"10.1016\/j.urolonc.2025.01.015_bib0028","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2025.01.015_bib0029","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.eururo.2021.10.009","article-title":"A molecular inquiry into the role of antibody-drug conjugates in Bacillus Calmette-Guerin-exposed non-muscle-invasive bladder cancer","volume":"81","author":"Choi","year":"2022","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925000146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:32:36Z","timestamp":1762363956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925000146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1078143925000146"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.01.015","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of baseline PD-L1 status in BCG naive nonmuscle invasive bladder cancer on outcomes and changes after BCG exposure","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}